To establish in vitro oviduct and OSE tumor development models, we utilized CRISPR-Cas9 technology to target the murine Trp53 gene alone or in combination with Brca1, Pten, and Nf1 (Fig. 3a-b). This evidence concerns the gene PTEN and neoplasm.